Clinical trials: Osteoporosis Postmenopausal
Postmenopausal Osteoporosis
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were…
- Trial name
- STRUCTURE (NCT01796301)
- Testing
- Romozosumab, Teriparatide
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 436 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis
To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.
- Trial name
- MORE (NCT00670319)
- Testing
- Raloxifene HCL
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 7,705 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women
This study will examine the biological fate of radioactive SB-751689 administered to healthy males and healthy postmenopausal women. Subjects will receive a single oral dose of radioactive SB-751689.
- Trial name
- NCT00499928
- Testing
- SB-751689
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteopenia, Osteoporosis
Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women
The primary objective of this clinical trial is to determine the effects of hesperidin on biochemical markers of bone in post-menopausal women.
- Trial name
- NCT00545116
- Testing
- Hesperidin
- Where
- Malaysia
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Osteoporosis
A Dose-response Study With Strontium Malonate in Postmenopausal Women
The primary objective of the study is to compare dose-response effect of three dose levels of strontium malonate to placebo on bone resorption quantified by S-CTX-1 following 12 weeks of treatment.
- Trial name
- NCT00409032
- Testing
- Strontium malonate
- Where
- 9 sites in Denmark, United Kingdom
- Volunteers
- 275 people
- Sponsor
- Osteologix
Osteoporosis, Age-Related
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
- Trial name
- NCT02732210
- Where
- 89 sites in United States, Canada
- Volunteers
- 935 people
- Sponsor
- Amgen
Osteoporosis, Postmenopausal
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).
- Trial name
- NCT00383422
- Testing
- Arzoxifene, Raloxifene
- Where
- 21 sites in United States, Argentina and 6 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Period, Osteoporosis, Postmenopausal
Angeliq Regulatory Post Marketing Surveillance
Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA).
- Trial name
- Angeliq rPMS (NCT01064453)
- Testing
- E2/DRSP (Angeliq, BAY86-4891)
- Where
- South Korea
- Volunteers
- 4,078 people
- Sponsor
- Bayer
Osteoarthritis
Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin
Relacatib is being developed for the treatment of osteoporosis, osteoarthritis and possibly other bone disorders. Recent results suggest that relacatib interacts with the way our bodies metabolise drugs and so some drugs which…
- Trial name
- NCT00411190
- Testing
- Relacatib, Acetaminophen, Ibuprofen
- Where
- 2 sites in Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis, Postmenopausal
Bindex for Osteoporosis Diagnostics
Osteoporosis is a disease that leads to impaired skeletal strength and increased fracture risk. Among 200 million osteoporotic patients most are diagnosed only after several fractures.
- Trial name
- NCT03878732
- Testing
- Bindex measurement
- Where
- United States
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- Bone Index Finland Ltd
Post-Menopausal Osteoporosis
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP)…
- Trial name
- NCT03432533
- Testing
- romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
- Where
- 46 sites in United States, Poland and 1 more
- Volunteers
- 283 people
- Sponsor
- Amgen
Post-Menopausal Osteoporosis
Intra-venous Zoledronic Acid Once Yearly
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment.
- Trial name
- IVORY (NCT00984893)
- Testing
- zoledronic acid, Any oral bisphosphonates marketed in Canada
- Where
- 3 sites in Canada
- Volunteers
- 1,551 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Osteoporosis
A Study of Quarterly Intravenous Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months.
- Trial name
- NCT00493532
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 14 sites in Taiwan
- Sponsor
- Hoffmann-La Roche
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
This 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg or 150mg Bonviva in women with post-menopausal osteoporosis who have previously completed Bonviva study BM16549 (MOBILE study).
- Trial name
- NCT00081653
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 31 sites in United States, Belgium and 12 more
- Volunteers
- 719 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)
The primary objective of this trial is to show that PTH(1-84) is superior to strontium ranelate in bone formation measured as changes in bone formation markers over a treatment period of 24 weeks in postmenopausal women with…
- Trial name
- NCT00479037
- Testing
- Full Length Parathyroid Hormone, PTH(1-84), Strontium Ranelate
- Where
- Denmark
- Volunteers
- 82 people
- Sponsor
- Nycomed
Osteoporosis, Postmenopausal
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.
- Trial name
- NCT00389740
- Testing
- MK0217, /Duration of Treatment : 12 Months, Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
- Volunteers
- 400 people
- Sponsor
- Organon and Co
Postmenopausal Women Osteoporosis
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with…
- Trial name
- NCT06804590
- Testing
- 9MW0311, Prolia®
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women with Osteoporosis at High Fracture Risk
- Trial name
- NCT07028320
- Testing
- SAL056 (56.5μg), Alendronate
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Osteoporosis, Postmenopausal
Efficacy and Safety of MW031 in PMO Subjects
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW031 in Chinese postmenopausal osteoporotic subjects with increased bone…
- Trial name
- NCT05215977
- Testing
- MW031
- Where
- China
- Volunteers
- 448 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Osteopenia, Osteoporosis
Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
The primary objective was to describe the safety and tolerability of up to 10 years or 7 years denosumab administration as measured by adverse event monitoring, immunogenicity and safety laboratory parameters in participants who…
- Trial name
- NCT00523341
- Testing
- Denosumab
- Volunteers
- 4,550 people
- Sponsor
- Amgen